The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amgen's drug Tavneos, used to treat a rare disorder, has been linked to 20 deaths in Japan according to reports originally published by The Wall Street Journal. This development has prompted local partner Kissei to issue official warnings advising caution when prescribing the medication. These reports place the drug's safety profile under intense regulatory scrutiny within the Asian markets.
Tavneos (avacopan) is a significant component of Amgen's rare disease portfolio, with global sales reaching approximately $173 million in Q1 2024 according to company earnings reports. Compared to biotech peers, AMGN stock faces potential pressure as investors monitor the reactions of regulators in the US and Europe, per market data. These concerns emerge at a time when major pharmaceutical firms are facing increased scrutiny over the side effects of innovative therapies.
Traders are monitoring AMGN price levels, which closed at $312.45 on May 15, 2026, while awaiting any official statements from the FDA regarding these reports. Looking at the economic calendar, upcoming Japanese inflation data and household spending updates (scheduled for May 11, 2026) may influence broader market sentiment in Japan, potentially impacting Amgen's local partnerships.